MTX652
Acute Kidney Injury (AKI) / Other
Pre-clinical/Phase 1Active
Key Facts
Indication
Acute Kidney Injury (AKI) / Other
Phase
Pre-clinical/Phase 1
Status
Active
Company
About Mission Therapeutics
Mission Therapeutics is a world leader in deubiquitylating enzyme (DUB) drug discovery and development, leveraging a proprietary platform to identify selective DUB inhibitors. Its lead programs, MTX325 and MTX652, target USP30 to enhance mitophagy and are in clinical development for Parkinson's disease and other conditions. The company is privately held, has raised significant capital and non-dilutive funding, and advances its pipeline through in-house development and strategic partnerships.
View full company profile